Munich, Germany - It is known that when bone marrow stem cells are injected intravenously into a recipient, the injected cells home to the recipient bone marrow because the bone marrow stroma secretes various chemoattractant factors that cause migration of cells. Along these lines, induction of tissue injury is also known to cause chemoattraction of bone marrow stem cells to the area of...
StemCellPatents.com Applauds Osiris Therapeutics for First Intravenous Allogeneic Stem Cell Clinical Data Mar 25 2007, 3:21 PM EST Business Wire StemCellPatents.com congratulates Osiris Therapeutics for promising data reported today using the PROVACEL™, adult mesenchymal stem cell product for treatment of post myocardial...
Saint-Mande, France - The ability of various stem cell types to be immune privileged is well known. For example, it is known that mesenchymal stem cells can act as veto cells under specific conditions. While mesenchymal stem cells are derived usually from the bone marrow, and it would make sense for them to suppress immune...
San Francisco, CA - Lee et al published (Antibody Targeting of Stem Cells to Infarcted Myocardium. Stem Cells. 2006 Nov 30; [Epub ahead of print]) a novel technique of increasing the concentration of stem cells to specific injured tissue. The investigators generated an antibody-like molecule of which one end binds to stem cells (well the actual antibody, anti-CD45) binds to many...
Frankfurt, Germany The concept of utilizing bone marrow cells to decrease scar tissue and improve patient prognosis after myocardial infarction has been previously tested clinically in patients. The majority of previous trials involved administration of autologous bone marrow within a certain time frame (usually 2-12 days) after the myocardial infarct. The reason for this is that...